All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CERC-006
Therapeutic Area: Rare Diseases and Disorders Product Name: CERC-006
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Calidi Biotherapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Details:
U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to CERC-006, a dual inhibitor of mTOR complexes 1 and 2 for the treatment of lymphatic malformations (LM).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IDE196
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2020
Details:
Preclinical studies will test IDE196, in vitro, to determine whether endothelial cells with GNAQ mutations can recover normal cell function as well as in vivo pharmacological inhibition of PKC.